Revive Therapeutics Completes Initial Funding for Future Growth
Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a pioneering life sciences company, has successfully closed the first tranche of its private placement offering. This strategic move is set to enhance the Company's ability to develop groundbreaking therapeutics for vital medical needs.
Details of the Private Placement Offering
The initial tranche raised substantial funds, with the issuance of 2,900,000 units at an attractive price of $0.021 per unit, amounting to total proceeds of approximately $60,900. Alongside this, Revive settled an outstanding note of $67,400 through the issuance of an additional 3,209,523 units, at the same unit price.
Composition of Each Unit
Each unit is composed of one common share and a warrant, offering investors the chance to acquire additional shares at an exercise price of $0.05 over the next three years. This structure not only provides immediate funds but also ensures that investors have potential upside in the Company's growth.
Strategic Use of Funds
The capital raised is earmarked for operational needs and the settlement of trade payables, effectively preserving cash for ongoing development projects. This approach underlines the Company’s commitment to maintaining strong financial health while progressing its innovative programs.
Compensation for Investment Services
In conjunction with this offering, Revive has issued compensation options to an investment dealer involved in the placement. This includes 100,000 compensation options, each enabling the dealer to purchase a ‘Compensation Unit’ at a similar price point, ensuring that all stakeholders are incentivized for their contributions.
Revive Therapeutics: A Leader in Innovative Therapeutics
Revive’s mission is clear: to innovate in the therapeutic landscape. The Company focuses on areas such as infectious diseases and medical countermeasures. A significant part of this endeavor involves exploring the therapeutic potential of Bucillamine, recognized for its promising role in treating various conditions, including serious nerve agent exposures.
Advancements in Psilocybin and Molecular Hydrogen Therapeutics
Additionally, Revive is making considerable strides in developing therapeutic programs centered around Psilocybin and molecular hydrogen. These programs aim to push the boundaries of medical science, offering new solutions to age-old problems.
Looking Ahead
Looking ahead, Revive Therapeutics is in a strong position to leverage recent funding toward promising developments. With a well-defined strategy that prioritizes rapid advancement and market entry in the face of regulatory challenges, they remain committed to their mission of addressing critical medical needs.
Contact Information
For inquiries regarding Revive Therapeutics and its initiatives, please reach out to:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Frequently Asked Questions
What did Revive Therapeutics recently accomplish?
Revive Therapeutics successfully closed the first tranche of its private placement, raising needed capital for development initiatives.
How much funding did Revive raise?
The initial tranche raised approximately $60,900 through the issuance of 2,900,000 units.
What are the components of a unit in this private placement?
Each unit comprises one common share and one share purchase warrant, providing investors a pathway to acquire additional shares.
How is Revive planning to use the raised funds?
The funds are designated for working capital and settling certain trade payables, helping maintain operational integrity.
What innovative therapeutic areas is Revive focused on?
Revive is exploring therapies targeting infectious diseases and is advancing compounds like Bucillamine and Psilocybin.
